Dear Editor,We report a case of recurrence after spontaneous separation of epiretinal membrane (ERM) in a young woman with suspected retinal vasculitis.ERM is defined as the fibrocellular membrane that proliferates on...Dear Editor,We report a case of recurrence after spontaneous separation of epiretinal membrane (ERM) in a young woman with suspected retinal vasculitis.ERM is defined as the fibrocellular membrane that proliferates on the inner surface of neurosensory retina at the macular area.Idiopathic ERM(iERM) usually occurs without a clearly identifiable cause in patients of more than 50 years of age and a great discrepancy in its prevalence from 1.02%to 28.9%among different ethnic groups were noted in previous epidemiologic studies^([1-3]).展开更多
The FDA has recently approved Krystal biotech's beremagene gep erpavec (B-VEC, Vyjuvek) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients. This represents a giant step, not only toward the tre...The FDA has recently approved Krystal biotech's beremagene gep erpavec (B-VEC, Vyjuvek) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients. This represents a giant step, not only toward the treatment of this devastating disease, but also for the whole field of non-replicative (nr) recombinant HSV-1vectors for gene therapy. To view this Bench to Bedside, open or download the PDF.展开更多
基金Supported by Beijing Natural Science Foundation (No.J190005)。
文摘Dear Editor,We report a case of recurrence after spontaneous separation of epiretinal membrane (ERM) in a young woman with suspected retinal vasculitis.ERM is defined as the fibrocellular membrane that proliferates on the inner surface of neurosensory retina at the macular area.Idiopathic ERM(iERM) usually occurs without a clearly identifiable cause in patients of more than 50 years of age and a great discrepancy in its prevalence from 1.02%to 28.9%among different ethnic groups were noted in previous epidemiologic studies^([1-3]).
文摘The FDA has recently approved Krystal biotech's beremagene gep erpavec (B-VEC, Vyjuvek) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients. This represents a giant step, not only toward the treatment of this devastating disease, but also for the whole field of non-replicative (nr) recombinant HSV-1vectors for gene therapy. To view this Bench to Bedside, open or download the PDF.
